These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 24016146)

  • 1. Systemic and local expression levels of TNF-like ligand 1A and its decoy receptor 3 are increased in primary biliary cirrhosis.
    Aiba Y; Harada K; Komori A; Ito M; Shimoda S; Nakamura H; Nagaoka S; Abiru S; Migita K; Ishibashi H; Nakanuma Y; Nishida N; Kawashima M; Tokunaga K; Yatsuhashi H; Nakamura M
    Liver Int; 2014 May; 34(5):679-88. PubMed ID: 24016146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum and synovial fluid levels of tumor necrosis factor-like ligand 1A and decoy receptor 3 in rheumatoid arthritis.
    Xiu Z; Shen H; Tian Y; Xia L; Lu J
    Cytokine; 2015 Apr; 72(2):185-9. PubMed ID: 25647275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis.
    Bamias G; Siakavellas SI; Stamatelopoulos KS; Chryssochoou E; Papamichael C; Sfikakis PP
    Clin Immunol; 2008 Nov; 129(2):249-55. PubMed ID: 18757243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis.
    Bamias G; Kaltsa G; Siakavellas SI; Papaxoinis K; Zampeli E; Michopoulos S; Zouboulis-Vafiadis I; Ladas SD
    Clin Immunol; 2010 Nov; 137(2):242-9. PubMed ID: 20675196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid.
    Chen L; Borozan I; Milkiewicz P; Sun J; Meng X; Coltescu C; Edwards AM; Ostrowski MA; Guindi M; Heathcote EJ; McGilvray ID
    Liver Int; 2008 Aug; 28(7):997-1010. PubMed ID: 18422935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression of the TL1A/DcR3 system of TNF/TNFR-like proteins in large vs. small intestinal Crohn's disease.
    Bamias G; Kaltsa G; Siakavellas SI; Gizis M; Margantinis G; Zampeli E; Vafiadis-Zoumboulis I; Michopoulos S; Daikos GL; Ladas SD
    Dig Liver Dis; 2012 Jan; 44(1):30-6. PubMed ID: 21978578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNFSF/TNFRSF cytokine gene expression in sickle cell anemia: Up-regulated TNF-like cytokine 1A (TL1A) and its decoy receptor (DcR3) in peripheral blood mononuclear cells and plasma.
    Safaya S; Alfarhan M; Sulaiman A; Alsulaiman A; Al-Ali A
    Cytokine; 2019 Nov; 123():154744. PubMed ID: 31255916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum decoy receptor 3 levels are associated with the disease activity of MPO-ANCA-associated renal vasculitis.
    Maruyama H; Hirayama K; Nagai M; Ebihara I; Shimohata H; Kobayashi M
    Clin Rheumatol; 2016 Oct; 35(10):2469-76. PubMed ID: 27251675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis.
    Neuman M; Angulo P; Malkiewicz I; Jorgensen R; Shear N; Dickson ER; Haber J; Katz G; Lindor K
    J Gastroenterol Hepatol; 2002 Feb; 17(2):196-202. PubMed ID: 11966951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
    Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
    Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased circulating levels of tumor necrosis factor-like cytokine 1A and decoy receptor 3 correlate with SYNTAX score in patients undergoing coronary surgery.
    Li XY; Hou HT; Chen HX; Wang ZQ; He GW
    J Int Med Res; 2018 Dec; 46(12):5167-5175. PubMed ID: 30213220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
    Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
    Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation and nuclear localization of TNF-like cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions.
    Bamias G; Evangelou K; Vergou T; Tsimaratou K; Kaltsa G; Antoniou C; Kotsinas A; Kim S; Gorgoulis V; Stratigos AJ; Sfikakis PP
    Exp Dermatol; 2011 Sep; 20(9):725-31. PubMed ID: 21672030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursodeoxycholic acid enhances fractional calcium absorption in primary biliary cirrhosis.
    Verma A; Maxwell JD; Ang L; Davis T; Hodges S; Northfield TC; Zaidi M; Pazianas M
    Osteoporos Int; 2002 Aug; 13(8):677-82. PubMed ID: 12181628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
    Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R
    Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR3 axis in patients with primary biliary cirrhosis: a possible novel mechanism of the effect of ursodeoxycholic acid.
    Manousou P; Kolios G; Drygiannakis I; Koulentaki M; Pyrovolaki K; Voumvouraki A; Notas G; Bourikas L; Papadaki HA; Kouroumalis E
    Clin Exp Immunol; 2013 Apr; 172(1):9-15. PubMed ID: 23480180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid.
    Joshi S; Cauch-Dudek K; Wanless IR; Lindor KD; Jorgensen R; Batts K; Heathcote EJ
    Hepatology; 2002 Feb; 35(2):409-13. PubMed ID: 11826416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
    Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
    Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of ursodeoxycholic acid in patients with primary biliary cirrhosis: sense or nonsense.
    Van Den Bogaert E; Francque S; Pelckmans P; Michielsen P
    Acta Gastroenterol Belg; 2003; 66(4):283-7. PubMed ID: 14989050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
    Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
    Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.